Plaquenil 200mg Film-coated Tablets/Hydroxychloroquine sulfate 200mg film-coated Tablets

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: myHealthbox

Aktif bileşen:

Hydroxychloroquine Sulfate

Mevcut itibaren:

Zentiva

ATC kodu:

P01BA02

INN (International Adı):

Hydroxychloroquine Sulfate

Doz:

200mg

Farmasötik formu:

Film-coated tablets

Uygulama yolu:

Oral use

Paketteki üniteler:

blister pack containing 56 or 60 tablets; bottle containing 56 or 100 tablets

Reçete türü:

POM - Prescription Only Medicine

Tarafından üretildi:

sanofi-aventis SA

Terapötik endikasyonlar:

Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or aggravated by sunlight in adults; Treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus erythematosus in children

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2015-03-05

Bilgilendirme broşürü

678923
678923

Ürün özellikleri

Plaquenil­Hydroxychloroquine sulfate 200mg FC Tabs
Summary of Product Characteristics Updated 12­Mar­2015 | Zentiva
1. Name of the medicinal product
Plaquenil 200mg Film­coated Tablets/Hydroxychloroquine sulfate 200mg film­coated Tablets
2. Qualitative and quantitative composition
Hydroxychloroquine Sulfate BP 200mg
3. Pharmaceutical form
Film coated tablet
White, round, film­coated tablets marked 'HCQ' on one side and '200' on the other side.
4. Clinical particulars
4.1 Therapeutic indications
_Adults_
Treatment of rheumatoid arthritis, discoid and systemic lupus erythematosus, and dermatological conditions caused or
aggravated by sunlight.
_Paediatric population_
Treatment of juvenile idiopathic arthritis (in combination with other therapies), discoid and systemic lupus
erythematosus.
4.2 Posology and method of administration
Adults (including the elderly)
The minimum effective dose should be employed. This dose should not exceed 6.5mg/kg/day (calculated from ideal
body weight and not actual body weight) and will be either 200mg or 400mg per day.
In patients able to receive 400mg daily:
Initially 400mg daily in divided doses. The dose can be reduced to 200mg when no further improvement is evident. The
maintenance dose should be increased to 400mg daily if the response lessens.
Paediatric population
The minimum effective dose should be employed and should not exceed 6.5mg/kg/day based on ideal body weight. The
200mg tablet is therefore not suitable for use in children with an ideal body weight of less than 31kg.
Each dose should be taken with a meal or glass of milk.
Hydroxychloroquine is cumulative in action and will require several weeks to exert its beneficial effects, whereas minor
side effects may occur relatively early. For rheumatic disease treatment should be discontinued�